Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3856 USD | -6.07% | -1.13% | -12.34% |
05-16 | Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024 | |
04-29 | AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.34% | 20.89M | |
+11.00% | 115B | |
+12.73% | 106B | |
-4.20% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-11.64% | 17.56B | |
-39.36% | 17.32B | |
+7.44% | 14.03B | |
+32.75% | 12.13B |
- Stock Market
- Equities
- AIM Stock
- News AIM ImmunoTech Inc.
- AIM ImmunoTech : Seeks Provisional Patent for Investigational Intranasal, Intravenous Therapy in Post-COVID-19 Dysfunction